Antibody specificity and related clinical features in antiphospholipid syndrome

References

• Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Ftheumatol 1986;13:486–9.
   Google Scholar
• Harris EN, Hughes GRV. Antiphospholipid antibodies. In: McCarty DJ, Koopman WJ, editors. Arthritis and allied conditions. 11th ed. Philadelphia (PA): Lea and Febiger; 1989. p. 1068–79.
   Google Scholar
• Harris EN. Antiphospholipid antibodies. Br J Haematol 1990;74: 1–9.
   PubMed Web of Science ®Google Scholar
• Harris EN. Antiphospholipid syndrome. In: Klippel JH, editor. Primer on the rheumatic diseases. 11th ed. Atlanta (GA): Arthris Foundation; 1997. p. 313–5.
   Google Scholar
• Kaburaki J. Antiphospholipid antibody syndrome (in Japanese). Ryumachi 1988;28:379–88.
   Google Scholar
• Kaburaki J, Homma M, Funatsu Y. Antiphospholipid syndrome (in Japanese). J Jpn Soc Intern Med 1990;79:1404–7.
   Google Scholar
• Kaburaki J. Clinical aspects of antiphospholipid syndrome (in Japanese). J Anal Bio-Sci 1997;20:331–40.
   Google Scholar
• Kaburaki J. Antiphospholipid syndrome-specificity of anti-phospholipid antibodies and thrombosis (in Japanese). Jpn J Clin Immunol 1999;22:1–12.
   Google Scholar
• Hughes GRV. Hughes' syndrome: the antiphospholipid syndrome. A historical review. Lupus 1998;7:S1–S4.
   Google Scholar
• Hughes GRV. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 1983;287:1088–9.
   Google Scholar
• Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GRV. Thrombosis in systemic lupus erythematosus: striking asso-ciation with the presence of circulating lupus anticoagulant. Br Med J 1983;287:1021–3.
   PubMed Web of Science ®Google Scholar
• Kaburaki J, Ikeda Y. Thrombosis in patients with SLE and antiphospholipid syndrome (in Japanese). Jpn J Clin Hematol 1995;36:320–4.
   Google Scholar
• Matsuura E. Anticardiolipin antibodies (in Japanese). Mebio 1994; 11:45–53.
   Google Scholar
• Pangborn MC. A new serologically active phospholipid from beef heart. Proc Soc Exp Biol Med 1941;48:484–6.
   Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
   PubMed Web of Science ®Google Scholar
• Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952;31:621–2.
   Web of Science ®Google Scholar
• Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagula-tion. Prog Hemost Thromb 1972;1:75–95.
   PubMedGoogle Scholar
• Shapiro SS, Thiagarajan P. Lupus anticoagulants. Prog Hemost Thromb 1982;6:263–85.
   PubMedGoogle Scholar
• Bowie EJW, Thompson JH Jr, Pascuzzi CA, Owen CA. Throm-bosis in systemic lupus erythematosus despite circulating anti-coagulants. J Lab Clin Med 1963;62:416–30.
   PubMed Web of Science ®Google Scholar
• Harris EN, Gharavi AE, Boey ML, Patel BM, Macworth-Young CG, Loizou S, et al. Anticardiolipin antibodies: detection by radio-immunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;2:1211–4.
   Google Scholar
• Koike T, Sueishi M, Funaki H, Tomioka H, Yoshida S. Anti-phospholipid antibodies and biological false-positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol 1984;56:193–9.
   Google Scholar
• Love PE, Santoro SA. Antiphospholipid antibodies: anticar-diolipin and the lupus anticoagulant in systemic lupus erythemato-sus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990;112:682–98.
   PubMed Web of Science ®Google Scholar
• McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: p2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120–4.
   PubMed Web of Science ®Google Scholar
• Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, Van Breda-Vriesman PJC, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544–7.
   Google Scholar
• Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of auto-immune disease. Lancet 1990;336:177–8.
   Google Scholar
• Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T, et al. Heterogeneity of anticardiolipin antibodies de-fined by the anticardiolipin cofactor. J Immunol 1992;148:3885–91.
   PubMed Web of Science ®Google Scholar
• Koike T, Ichikawa K, Atsumi T, Kasahara H, Matsuura E.132-glycoprotein I-anti-132-glycoprotein I interaction. J Autoimmun 2000;15: 97–100.
   Google Scholar
• Hunt J, Krilis S. The fifth domain of 32-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recog-nized by anticardiolipin antibodies. J Immunol 1994;152:653–9.
   PubMed Web of Science ®Google Scholar
• Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize 32-glycoprotein I structure altered by interacting with an oxygen-modified solid-phase surface. J Exp Med 1994;179: 457–62.
   Google Scholar
• Takeya H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E, et al. Anti-32-glycoprotein I (GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the 132GPI binding to phospholipids. J Clin Invest 1997;99:2260–8.
   PubMed Web of Science ®Google Scholar
• Reddel SW, Wang IX, Sheng YH, Krilis SA. Epitope studies with 51. anti-32-glycoprotein I antibodies from autoantibody and immu-nized sources. J Autoimmun 2000;15:91–6.
   Google Scholar
• Roubey FtAS, Eisenberg RA, Harper MF, Winfield JB. 52. "Anticardiolipin" autoantibodies recognize 32-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995;154: 954–60.
   Google Scholar
• Takamatsu K, Kishino W, Suehiro T, Yamano T, Ohno F. Plasma 53. apolipoprotein H (p2-glycoprotein I) phenotype frequencies in a Japanese population. Jpn J Hum Genet 1989;34: 279–83.54.
   Google Scholar
• Yasuda S, Atsumi T, Ichikawa K, Matsuura E, Kaihara K, Yasuda T, et al. Valine/leucinew polymorphism of 32-glycoprotein I affects the reactivity of anti-132-glycoprotein I antibodies. Arthritis Rheum 55. 2000;43:5404.
   Google Scholar
• Hattori N, Kuwana M, Kaburaki J, Mimori T, Ikeda Y, Kawakami Y. T cells that are autoreactive to 32-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum 2000;43:65-75.56.
   Google Scholar
• Arai T, Yoshida K, Hattori N, Kaburaki J, Ikeda Y, Kawakami Y, et al. Characterization of autoreactive T cell clones to 32-57. glycoprotein I in patients with antiphospholipid syndrome. Arthritis Rheum 2000;43:5306.
   Google Scholar
• Yoshida K, Arai T, Hattori N, Kaburaki J, Ikeda Y, Kawakami Y, 58. et al. Highly restricted T cell receptor 3-chain usage in autoreactive T cells to 32-glycoprotein I. Arthritis Rheum 2000;43: 5306.
   Google Scholar
• Kaburaki J, Kuwana M, Ikeda Y, Yamamoto M, Kawai S, 59. Matsuura E. Cofactor (p2-glycoprotein I)-dependent anticardio-lipin antibodies and thrombosis. J Ftheumatol 1994;21: 1371–2.
   Google Scholar
• Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Matsuura E, Ikeda Y. Disease distribution of 32-glycoprotein I-dependent 60. anticardiolipin antibodies in rheumatic diseases. Lupus 1995;4: S27–S31.
   Google Scholar
• Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Matsuura E, 61. Ikeda Y. Clinical significance of phospholipid-dependent anti-132-glycoprotein I (p2-GPI) antibodies in systemic lupus erythemato-sus. Lupus 1995;4: 472–6.
   Google Scholar
• Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Matsuura E, 62. Ikeda Y. Phospholipid-dependent anti-132-glycoprotein I (p2-GPI) antibodies and antiphospholipid syndrome. Intern Med 1996;35: 105–10.63.
   Google Scholar
• Kaburaki J, Kuwana M, Ikeda Y. Anti-cardiolipin-132-GPI complex antibodies in idiopathic thrombocytopenic purpura. Intern Med 1998;37: 796.
   Google Scholar
• Tsutsumi A, Matsuura E, Ichikawa K, Fujisaki A, Mukai M, 64. Kobayashi S, et al. Antibodies to 32-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. 65. Arthritis Rheum 1996;39: 1466–74.
   Google Scholar
• Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 66. 1983;61:684–92.
   Google Scholar
• Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. 67. Thromb Haemost 1995;74:1120–5.
   PubMed Web of Science ®Google Scholar
• Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, 68. Matsuura E, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus 69. anticoagulant. Arthritis Rheum 2000;43: 1982–93.
   Google Scholar
• Galli M. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome? J Autoimmun 2000;15:101-5.70.
   Google Scholar
• Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on lupus anticoagulant/antiphospholipid antibody of the Scientific and Standardisation Committee of the ISTH. 71. Thromb Haemost 1995;74:1185–90.
   Google Scholar
• Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal FtFA. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, 72. but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66: 629–32.
   Google Scholar
• Roubey FtAS, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagu-lant activity of autoimmune antiphospholipid antibodies is depen- 73. dent upon 32-glycoprotein I. J Clin Invest 1992;90: 1100–4.
   Google Scholar
• Permpikul P, Rao LVM, Rapaport SI. Functional and binding studies of the roles of prothrombin and 32-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994;83: 2878–92.
   Google Scholar
• Pengo V, Biasiolo A, Rampazzo P, Brocco T. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-132-glycoprotein I autoantibodies. Thromb Haemost 1999;81:256–8.
   PubMed Web of Science ®Google Scholar
• Triplett DA. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. J Autoimmun 2000;15:173–8.
   PubMedGoogle Scholar
• Vermylen J, Arnout J. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes? J Lab Clin Med 1992;120:10–2.
   PubMedGoogle Scholar
• Oosting JD, Derksen FtHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618–25.
   Google Scholar
• Kapur A, Kelsey PR, Isaacs PET. Factor V inhibitor in thrombosis. Am J Hematol 1993;42:384–8.
   Google Scholar
• Funakoshi T, Heimark RL, Hendrickson LE, McMullen BA, Fujikawa K. Human placental anticoagulant protein: isolation and characterization. Biochemistry 1987;26:5572–8.
   Google Scholar
• Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 1997;54:209–13.
   Google Scholar
• Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol 1994;47:56–8.
   Google Scholar
• Matsuda J, Gotoh M, Saitoh N, Gohchi K, Tsukamoto M, Yamamoto T. Anti-annexin antibody in the sera of patients with habitual fetal loss or preeclampsia. Thromb Res 1994;75:105–6.
   PubMedGoogle Scholar
• Sugi T, Katsunuma J, Izumi S, McIntyre JA, Makino T. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril 1999;71: 1060–5.
   Google Scholar
• Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanola-mine (PE) recognize a kininogen-PE complex. Blood 1995;86: 3083–9.
   PubMed Web of Science ®Google Scholar
• Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of 32-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macro-phages. Clin Exp Immunol 1997;107:569–73.
   PubMed Web of Science ®Google Scholar
• Matsuura E, Kobayashi K, Yasuda T, Koike T. Antiphospholipid antibodies and atherosclerosis. Lupus 1998;7:5135–5139.
   Google Scholar
• Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Cross-reaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythema-tosus. Lancet 1993;341:923–5.
   Google Scholar
• Romero Fl, Atsumi T, Tinahones FJ, Gomez-Zumaquero JM, Amengual O, Khamashta MA, et al. Autoantibodies against malondialdehyde-modified lipoprotein (a) in antiphospholipid syndrome. Arthritis Rheum 1999;42:2606–11.
   Google Scholar
• Kaburaki J. Clinical features and pathogenesis of catastrophic antiphospholipid syndrome. Intern Med 2000;39:763–4.
   Google Scholar
• Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Chin Invest 1995;96:2211–9.
   PubMed Web of Science ®Google Scholar
• Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A, et al. Endothelial activation by aPL: a potential pathogenic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000;15:237–40.
   PubMed Web of Science ®Google Scholar
• Oosting JD, Preissner KT, Derksen RHWM, de Groot PG. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 1993;85:761–8.
   Google Scholar
• Shibata S, Harpel P, Bona C, Fillit H. Monoclonal antibodies to heparan sulfate inhibit the formation of thrombin-antithrombin III complexes. Clin Immunol Immunopathol 1993;67:264–72.
   PubMedGoogle Scholar
• Shibata S, Harpel PC, Gharavi A, Rand J, Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994;83:2532–40.
   Google Scholar
• Trimble M, Bell DA, Brien W, Hachinski V, O'Keefe B, McLay C, et al. The antiphospholipid syndrome: prevalence among patients with stroke and transient ischemic attacks. Am J Med 1990;88:593–7.
   Google Scholar
• Piette J-C. Towards improved criteria for the antiphospholipid syndrome. Lupus 1998;7:S149–S157.
   Google Scholar
• Godeau B, Piette J-C, Fromont P, Intrator L, Schaeffer A, Bierling P. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol 1997;98:873–9.
   Google Scholar
• Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette J-C, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an international workshop. Arthritis Rheum 1999;42: 1309–11.
   Google Scholar
• Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000;43:440–3.
   PubMed Web of Science ®Google Scholar
• Roubey FtAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994;84:2854–67.
   Google Scholar
• Roubey FtAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996;39:1444–54.
   Google Scholar
• Roubey FtAS. Mechanisms of autoantibody-mediated thrombosis. Lupus 1998;7:5114–5119.
   Google Scholar
• Branch DW, Dudley DJ, Mitchell MD, Creighton KA, Abbott TM, Hammond EH, et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990;163:210–6.
   PubMed Web of Science ®Google Scholar
• Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome in naïve mice with mouse lupus monocloncal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 1991;88:3069–73.
   PubMed Web of Science ®Google Scholar
• Branch DW. Thoughts on the mechanism of pregnancy loss associ-ated with the antiphospholipid syndrome. Lupus 1994;3:275–80.
   Google Scholar
• Magid MS, Kaplan C, Sammaritano LR, Peterson M, Druzin ML, Lockshin MD. Placental pathology in systemic lupus erythemato-sus: a prospective study. Am J Obstet Gynecol 1998;179:226–34.
   PubMed Web of Science ®Google Scholar
• Shurtz-Swirski R, Inbar O, Blank M, Cohen J, Bakimer R, Barnea ER, et al. In vitro effect of anticardiolipin autoantibodies upon total and pulsatile placental hCG secretion during early pregnancy. Am J Reprod Immunol 1993;29:206–10.
   Google Scholar
• Rand JH, Wu X-X, Guller S, Gil J, Guha A, Scher J, et al. Reduc-tion of annexin V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994;171:1566–72.
   Google Scholar
• Petri M. Pathogenesis and treatment of the antiphospholipid anti-body syndrome. Adv Ftheumatol 1997;81:151–77.
   Google Scholar
• Khamashta MA. Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus 1998;7:5162–5165.
   Google Scholar
• Khamashta MA. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. J Autoimmun 2000;15:249–53.
   PubMed Web of Science ®Google Scholar
• Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303–8.
   PubMed Web of Science ®Google Scholar
• Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993–7.
   PubMed Web of Science ®Google Scholar
• Macworth-Young CG, Andreotti F, Harmer I, Loizou S, Pottinger BE, Pearson JD, et al. Endothelium-derived haemostatic factors and the antiphospholipid syndrome. Br J Ftheumatol 1995;34:201–6.
   Google Scholar
• Kaburaki J, Kuwana M, Suzuki K, Ikeda Y. Activated protein C-protein C inhibitor complex is a sensitive marker of the coagulation-fibrinolysis system in patients with antiphospholipid antibodies. Arthritis Rheum 1998;41:S171.
   Google Scholar
• Asherson RA. The catastrophic antiphospholipid syndrome. J Ftheumatol 1992;19:508–12.
   Google Scholar
• Asherson RA, Cervera R, Piette J-C, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine 1998;77: 195–207.
   Google Scholar
• Rai R. Obstetric management of antiphospholipid syndrome. J Autoimmun 2000;15:203–7.
   Google Scholar